Early results from the ongoing QUILT-106 clinical trial (NCT06334991) show that the treatment combination of CD19 chimeric antigen receptor natural killer (CAR-NK) cells with rituximab (Rituxan) can ...
Clinical Trials Arena on MSN
ImmunityBio’s allogeneic CD19 cell therapy shows complete response beyond 15 months
ImmunityBio’s stock is up after its off-the-shelf allogeneic CD19 chimeric antigen receptor natural killer cell therapy ...
Friday, ImmunityBio said the two complete responses are ongoing after seven and 15 months. The patients received four cycles ...
The patient with significant bone marrow involvement had complete bone morphological remission. In this patient in which 95% ...
A pair of patients with Waldenstrom’s non-Hodgkins lymphoma (NHL) remain in complete remission (CR) after 7 and 15 months ...
US biotech ImmunityBio has reported two ongoing complete remissions lasting seven and 15 months in patients with Waldenstrom ...
News-Medical.Net on MSN
Recent advances in CAR-NK cell therapy could revolutionze cancer treatment
Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...
Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with ...
CD19 CAR NK cell therapy, alone or with rituximab, shows promise in relapsed/refractory B-cell NHL, including Waldenström macroglobulinemia. Two heavily pretreated WM patients achieved complete ...
Hangzhou Qihan Biotech Co., Ltd. (“Qihan” or “Qihan Biotech” or “the Company”), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, ...
A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback